These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37390764)

  • 1. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
    ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
    Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
    Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
    Nakagawa K; Nadal E; Garon EB; Nishio M; Seto T; Yamamoto N; Park K; Shih JY; Paz-Ares L; Frimodt-Moller B; Zimmermann AH; Wijayawardana S; Visseren-Grul C; Reck M
    Clin Cancer Res; 2021 Oct; 27(19):5258-5271. PubMed ID: 34301751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
    Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
    Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
    Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
    Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with
    Nishio K; Sakai K; Nishio M; Seto T; Visseren-Grul C; Carlsen M; Matsui T; Enatsu S; Nakagawa K
    Transl Lung Cancer Res; 2023 Aug; 12(8):1702-1716. PubMed ID: 37691865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RELAY, Erlotinib Plus Ramucirumab in Untreated,
    Nishino K; Shih JY; Nakagawa K; Reck M; Garon EB; Carlsen M; Matsui T; Visseren-Grul C; Nadal E
    JTO Clin Res Rep; 2024 Feb; 5(2):100624. PubMed ID: 38304857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
    Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
    Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
    Chiu CH; Lin MC; Wei YF; Chang GC; Su WC; Hsia TC; Su J; Wang AK; Jen MH; Puri T; Shih JY
    Target Oncol; 2023 Jul; 18(4):505-515. PubMed ID: 37329423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic
    Nishio K; Seto T; Nishio M; Reck M; Garon EB; Sakai K; Goto K; Kato T; Nakanishi Y; Takahashi T; Yamamoto N; Kiura K; Ohe Y; Tamura T; Visseren-Grul C; Frimodt-Moller B; Hozak RR; Wijayawardana SR; Zimmermann A; Homma G; Enatsu S; Nakagawa K
    JTO Clin Res Rep; 2021 Jun; 2(6):100171. PubMed ID: 34590023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
    Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
    Felip E; Cho BC; Gutiérrez V; Alip A; Besse B; Lu S; Spira AI; Girard N; Califano R; Gadgeel SM; Yang JC; Yamamoto S; Azuma K; Kim YJ; Lee KH; Danchaivijitr P; Ferreira CG; Cheng Y; Sendur MAN; Chang GC; Wang CC; Prabhash K; Shinno Y; Stroyakovskiy D; Paz-Ares L; Rodriguez-Cid JR; Martin C; Campelo MRG; Hayashi H; Nguyen D; Tomasini P; Gottfried M; Dooms C; Passaro A; Schuler M; Gelatti ACZ; Owen S; Perdrizet K; Ou SI; Curtin JC; Zhang J; Gormley M; Sun T; Panchal A; Ennis M; Fennema E; Daksh M; Sethi S; Bauml JM; Lee SH
    Ann Oncol; 2024 Sep; 35(9):805-816. PubMed ID: 38942080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
    Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K;
    Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
    Clement MS; Ebert EBF; Meldgaard P; Sorensen BS
    Clin Lung Cancer; 2021 Nov; 22(6):e870-e877. PubMed ID: 34140247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
    Li Y; Xu Z; Wang S; Zhu Y; Ma D; Mu Y; Ying J; Li J; Xing P
    Thorac Cancer; 2022 Aug; 13(15):2201-2209. PubMed ID: 35778830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
    Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.